8-K filings and company releases
Company news
3 articles on Lilly(Eli).
Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first. Each one links to the filing or release it was written from.Articles GetSignal writes with AI from a company's own 8-K filing or press release, newest first.
Free on iOS and Android
LLY articles
Newest first, 25 to a page- Company release
Nov 11, 2026 · Company release
Eli Lilly says Taltz with Zepbound improved psoriatic arthritis outcomes at one year
In the TOGETHER-PsA trial, 43.7% of patients on both drugs achieved ACR50 at one year, versus 15.7% on Taltz alone.
- Form 8-K
Aug 5, 2026 · Form 8-K
Eli Lilly says it now expects 2026 revenue of $85 billion to $87 billion
Eli Lilly said its 2026 non-GAAP earnings per share range is $35.50 to $36.50, down from $35.50 to $37.00, and excludes acquired IPR&D incurred after June 30, 2026.
- Form 8-K
May 7, 2026 · Form 8-K
Eli Lilly shareholders elect four directors at May 4 annual meeting
Proposals to eliminate the classified board and supermajority voting did not reach the 80% vote required.
How these are written
- The source: the company's own 8-K filing or press release, linked from every article. What the company says is attributed to the company.
- The checks: each article is written by GetSignal with AI and checked against its source before it is shown.
- The date: the day the company filed the 8-K or published the release.
- Not investment advice. An article reports what the company disclosed; it is not a view on the stock.